

Package leaflet: Information for the patient

Sacubitril/Valsartan DOC 24 mg/26 mg, filmomhulde tabletten
Sacubitril/Valsartan DOC 49 mg/51 mg, filmomhulde tabletten
Sacubitril/Valsartan DOC 97 mg/103 mg, filmomhulde tabletten
sacubitril/valsartan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What <Invented name> is and what it is used for
2. What you need to know before you take <Invented name>
3. How to take <Invented name>
4. Possible side effects
5. How to store <Invented name>
6. Contents of the pack and other information

1. What <Invented name> is and what it is used for

<Invented name> is a heart medicine containing an angiotensin receptor neprilysin inhibitor. It delivers two active substances, sacubitril and valsartan.

<Invented name> is used to treat a type of long-term heart failure in adults, children and adolescents (one year and older).

This type of heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and the rest of the body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.

2. What you need to know before you take <Invented name>

Do not take <Invented name>

- if you are allergic to sacubitril, valsartan or any of the other ingredients of this medicine (listed in section 6).
- if you are taking another type of medicine called an angiotensin converting enzyme (ACE) inhibitor (for example enalapril, lisinopril or ramipril), which is used to treat high blood pressure or heart failure. If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take <Invented name> (see “Other medicines and <Invented name>”).
- if you have ever had a reaction called angioedema (rapid swelling under the skin in areas such as the face, throat, arms and legs which can be life threatening if throat swelling blocks the airway) when taking an ACE inhibitor or an angiotensin receptor blocker (ARB) (such as valsartan, telmisartan or irbesartan).
- if you have a history of angioedema which is hereditary or for which the cause is unknown (idiopathic).
- if you have diabetes or impaired kidney function and you are being treated with a blood pressure lowering medicine containing aliskiren (see “Other medicines and <Invented name>”).
- if you have severe liver disease.

- if you are more than 3 months pregnant (see “Pregnancy and breast-feeding”).

If any of the above applies to you, do not take <Invented name> and talk to your doctor.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before or when taking <Invented name>:

- if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see “Do not take <Invented name>”).
- if you have ever had angioedema (see “Do not take <Invented name>” and section 4 “Possible side effects”).
- if you experience abdominal pain, nausea, vomiting or diarrhoea after taking <Invented name>. Your doctor will decide on further treatment. Do not stop taking <Invented name> on your own.
- if you have low blood pressure or are taking any other medicines that reduce your blood pressure (for example, a medicine that increases urine production (diuretic)) or are suffering from vomiting or diarrhoea, especially if you are aged 65 years or more, or if you have kidney disease and low blood pressure.
- if you have kidney disease.
- if you are suffering from dehydration.
- if your kidney artery has narrowed.
- if you have liver disease.
- if you experience hallucinations, paranoia or changes in sleeping pattern while taking <Invented name>.
- if you have hyperkalaemia (high levels of potassium in the blood).
- if you suffer from heart failure classified as NYHA class IV (unable to carry on any physical activity without discomfort and may have symptoms even when resting).

If any of the above applies to you, tell your doctor, pharmacist or nurse before you take <Invented name>.

Your doctor may check the amount of potassium and sodium in your blood at regular intervals during <Invented name> treatment. In addition, your doctor may check your blood pressure at start of treatment and when the doses are increased.

Children and adolescents

Do not give this medicine to children aged below 1 year because it has not been studied in this age group. For children one year and older with a body weight below 40 kg, other pharmaceutical forms of sacubitril / valsartan containing medicinal products are more suitable; ask your doctor or pharmacist.

Other medicines and <Invented name>

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. It may be necessary to change the dose, to take other precautions, or even to stop taking one of the medicines. This is particularly important for the following medicines:

- ACE inhibitors. Do not take <Invented name> with ACE inhibitors. If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take <Invented name> (see “Do not take <Invented name>”). If you stop taking <Invented name>, wait 36 hours after taking your last dose of <Invented name> before starting an ACE inhibitor.
- other medicines used to treat heart failure or lower blood pressure, such as angiotensin receptor blockers or aliskiren (see “Do not take <Invented name>”).
- some medicines known as statins that are used to lower high cholesterol levels (for example atorvastatin).
- sildenafil, tadalafil, vardenafil or avanafil, which are medicines used to treat erectile dysfunction or lung hypertension.
- medicines that increase the amount of potassium in the blood. These include potassium supplements, salt substitutes containing potassium, potassium-sparing medicines and heparin.

- painkillers of the type called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 (Cox-2) inhibitors. If you are taking one of these, your doctor may want to check your kidney function when starting or adjusting treatment (see “Warnings and precautions”).
- lithium, a medicine used to treat some types of psychiatric illness.
- furosemide, a medicine belonging to the type known as diuretics, which are used to increase the amount of urine you produce.
- nitroglycerine, a medicine used to treat angina pectoris.
- some types of antibiotics (rifamycin group), ciclosporin (used to prevent rejection of transplanted organs) or antivirals such as ritonavir (used to treat HIV/AIDS).
- metformin, a medicine used to treat diabetes.

If any of the above applies to you, tell your doctor or pharmacist before you take <Invented name>.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy

You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of <Invented name>.

This medicine is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.

Breast-feeding

<Invented name> is not recommended for mothers who are breast-feeding. Tell your doctor if you are breast-feeding or about to start breast-feeding.

Driving and using machines

Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how <Invented name> affects you. If you feel dizzy or very tired while taking this medicine, do not drive a vehicle, cycle or use any tools or machines.

<Invented name> contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per 97 mg/103 mg dose, that is to say essentially ‘sodium free’.

3. How to take <Invented name>

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Adults

You will usually start by taking a 24 mg/26 mg or 49 mg/51 mg tablet twice a day (one tablet in the morning and one tablet in the evening). Your doctor will decide your exact starting dose based on which medicines you have been taking previously and your blood pressure. Your doctor will then adjust the dose every 2-4 weeks depending on how you respond to the treatment until the best dose for you is found.

The usual recommended target dose is 97 mg/103 mg twice a day (one tablet in the morning and one tablet in the evening).

Children and adolescents (one year and older)

Your (or your child’s) doctor will decide the starting dose based on body weight and other factors

including previously taken medicines. The doctor will adjust the dose every 2-4 weeks until the best dose is found.

<Invented name> should be given twice a day (one tablet in the morning and one tablet in the evening).

<Invented name> film-coated tablets are not meant to be used in children who weigh less than 40 kg. Sacubitril / valsartan containing medicinal products in other pharmaceutical forms are available for these patients.

Patients taking <Invented name> can develop low blood pressure (dizziness, light-headedness), a high level of potassium in the blood (which would be detected when your doctor performed a blood test) or decreased kidney function. If this happens, your doctor may reduce the dose of any other medicine you are taking, temporarily reduce the <Invented name> dose, or stop <Invented name> treatment completely.

Swallow the tablets with a glass of water. You can take <Invented name> with or without food. Splitting or crushing of the tablets is not recommended.

If you take more <Invented name> than you should

If you have accidentally taken too many <Invented name> tablets, or if someone else has taken your tablets, contact your doctor immediately. If you experience severe dizziness and/or fainting, tell your doctor as quickly as possible and lie down.

If you forget to take <Invented name>

It is advisable to take your medicine at the same time each day. However, if you forget to take a dose, you should simply take the next one at the scheduled time. Do not take a double dose to make up for a forgotten dose.

If you stop taking <Invented name>

Stopping your treatment with <Invented name> may cause your condition to get worse. Do not stop taking your medicine unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects may be serious.

- Stop taking <Invented name> and seek immediate medical attention if you notice any swelling of the face, lips, tongue and/or throat, which may cause difficulties in breathing or swallowing. These may be signs of angioedema (an uncommon side effect which may affect up to 1 in 100 people).

Other possible side effects:

If any of the side effects listed below becomes severe, tell your doctor or pharmacist.

Very common (may affect more than 1 in 10 people)

- low blood pressure, which can cause symptoms of dizziness and light-headedness (hypotension)
- high level of potassium in the blood, shown in a blood test (hyperkalaemia)
- decreased kidney function (renal impairment)

Common (may affect up to 1 in 10 people)

- cough

- dizziness
- diarrhoea
- low level of red blood cells, shown in a blood test (anaemia)
- tiredness (fatigue)
- (acute) inability of the kidney to work properly (renal failure)
- low level of potassium in the blood, shown in a blood test (hypokalaemia)
- headache
- fainting (syncope)
- weakness (asthenia)
- feeling sick (nausea)
- low blood pressure (dizziness, light-headedness) when switching from sitting or lying to standing position
- gastritis (stomach pain, nausea)
- spinning sensation (vertigo)
- low level of sugar in the blood, shown in a blood test (hypoglycaemia)

Uncommon (may affect up to 1 in 100 people)

- allergic reaction with rash and itching (hypersensitivity)
- dizziness when switching from sitting to standing position (dizziness postural)
- low level of sodium in the blood, shown in a blood test (hyponatraemia)

Rare (may affect up to 1 in 1 000 people)

- seeing, hearing or feeling things that are not there (hallucinations)
- changes in sleeping pattern (sleep disorder)

Very rare (may affect up to 1 in 10 000 people)

- paranoia
- intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting and diarrhoea

Not known (frequency cannot be estimated from the available data)

- sudden involuntary muscle twitching (myoclonus)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store <Invented name>

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special temperature storage conditions.

Store in the original package in order to protect from moisture.

Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What <Invented name> contains

- The active substances are sacubitril and valsartan.
 - Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan.
 - Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan.
 - Each 97 mg/103 mg film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan.
- The other ingredients in the tablet core are microcrystalline cellulose (E460(i)), low-substituted hydroxypropylcellulose (E463), crospovidone, magnesium stearate and talc (E553b) (see end of section 2 under ‘<Invented name> contains sodium’).
- The 24 mg/26 mg and the 97 mg/103 mg tablet coatings contain hypromellose, titanium dioxide (E171), talc (E553b), Macrogol (4000), iron oxide red (E172) and iron oxide black (E172).
- The 49 mg/51 mg tablet coating contains hypromellose, titanium dioxide (E171), talc (E553b), Macrogol (4000), iron oxide yellow (E172) and iron oxide red (E172).

What <Invented name> looks like and contents of the pack

<Invented name> 24 mg/26 mg film-coated tablets are violet white round film-coated tablets, unscored, debossed with “L” on one side, plain on the other side.

Approximate tablet diameter 6.0 mm.

<Invented name> 49 mg/51 mg film-coated tablets are pale yellow ovaloid biconvex film-coated tablets, unscored, with bevelled edges, debossed with “I” on one side and plain on the other side.

Approximate tablet dimensions 13.1 mm x 5.2 mm.

<Invented name> 97 mg/103 mg film-coated tablets are light pink, ovaloid biconvex film-coated tablets, unscored, with beveled edges debossed with "H" on one side, plain on the other side.

Approximate tablets dimensions 15.1 x 6.0 mm.

The tablets are supplied in packs containing 28 and 56 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Houder van de vergunning voor het in de handel brengen:

DOC Generici S.r.l.

Via Turati 40,

Milaan 20121

Italië

Fabrikanten:

Elpen Pharmaceutical Co. Inc.

Marathonos Avenue 95

Pikermi, Attiki

190 09 Griekenland

Elpen Pharmaceutical Co. Inc.

Keratea Industrial Park

Zapani, Block 1048

Keratea, Attiki

190 01 Griekenland

Pharmacare Premium Limited

HHF003 Hal Far Industrial Estate

Birzebugia,

BBG 3000, Malta

In het register ingeschreven onder:

Sacubitril/Valsartan DOC 24 mg/26 mg, filmomhulde tabletten: RVG 132725

Sacubitril/Valsartan DOC 49 mg/51 mg, filmomhulde tabletten: RVG 132726

Sacubitril/Valsartan DOC 97 mg/103 mg, filmomhulde tabletten: RVG 132727

This medicinal product is authorised in the Member States of the EEA under the following names:

Nederland	Sacubitril/Valsartan DOC 24 mg/26 mg, filmomhulde tabletten Sacubitril/Valsartan DOC 49 mg/51 mg, filmomhulde tabletten Sacubitril/Valsartan DOC 97 mg/103 mg, filmomhulde tabletten
Italië	SACUBITRIL E VALSARTAN DOC

Deze bijsluiter is voor het laatst goedgekeurd in januari 2026.